In this BrightFocus Foundation webinar, Dr Roberta Diaz Brinton, Director of the Center for Innovation in Brain Science at the University of Arizona, introduces the ReGenBRAIN Phase 2 clinical trial. The study is testing whether the drug allopregnanolone (“Allo”) can help repair brain damage and improve thinking in people with mild Alzheimer’s disease who carry the APOE ε4 genetic risk factor.
Dr Brinton explains how Allo works, the science behind brain regeneration, and the results seen so far. She discusses who can enrol, trial locations, how the treatment is given, and why this approach offers hope for slowing or reversing damage in Alzheimer’s.
Watch to learn more about the trial’s goals, its potential impact, and the broader effort to bring regenerative therapies to people living with dementia.
Alzheimer's Association
Alz Forum
